ARCT
Arcturus TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Composite grade F from latest DB weights. Momentum 7.1 / Value 58.5
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
7
Value
58
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $20.60
Why
Momentum7 · Δ7d -1.5
Value58 · Δ7d -0.2
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
7
40% active weight
Current posture
7d trendImproving
Δ7d
-1.5
Δ21d
+4.6
Value
58
60% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+17.3
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 7.1 / Value 58.5
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$168.55M
Beta
2.38
Shares Out
28.42M
P/E (TTM) · Derived
-2.5
P/S (TTM)
2.42
P/FCF (TTM) · Derived
-2.61
Rev YoY
-97.6%
EPS YoY
+82.7%
Gross Margin
+93.1%
Op Margin
-80.3%
Net Debt
-$205.91M
Current Ratio
6.31
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology